Application of Gene Therapy in Hemophilia

Abstract

Gene therapy refers to introducing normal exogenous genes into target cells to correct or compensate for the diseases caused by defective and abnormal genes for the purpose of therapy. It holds out hope of a cure for single-gene genetic diseases such as thalassemia, hemophilia, etc. At present, gene therapy is performed in two ways: introducing exogenous genes, and gene editing. A great number of clinical trials of gene therapy in hemophilia have been carried out using viral vectors to introduce foreign genes into target cells. However, the production of neutralizing antibodies following injection and the inability to prepare viral vectors in large quantities limit their application. Although gene-editing methods like CRISPR avoid the above problems, the potential risks of off-target effects are still unknown. More trials and evidence are needed to elucidate the safety and accuracy of gene therapy. This paper will review the bench and clinical work of gene therapy in hemophilia in recent years, and summarize the challenges and prospects of gene therapy, so as to provide directions for future scientific research in this field.

Keywords

hemophilia / gene therapy / CRISPR-Cas9 / application

References

[1] HartmannJ, CroteauSE. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol, 2016, 91(12): 1252-1260

[2] ArrudaVR, DoshiBS, Samelson-JonesBJ. Novel approaches to hemophilia therapy: successes and challenges. Blood, 2017, 130(21): 2251-2256

[3] EvensH, ChuahMK, VandenDriesscheT. Haemophilia gene therapy: From trailblazer to gamechanger. Haemophilia, 2018, 24(Suppl 6): 50-59

[4] NathwaniAC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program, 2019, 2019(1): 1-8

[5] PrakashV, MooreM, Yáñez-MuñozRJ. Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther, 2016, 24(3): 465-474

[6] MeijersJC, TekelenburgWL, BoumaBN, et al.. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med, 2000, 342(10): 696-701

[7] JenkinsPV, RawleyO, SmithOP, et al.. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol, 2012, 157(6): 653-663

[8] NasoMF, TomkowiczB, PerryWL3rd, et al.. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs, 2017, 31(4): 317-334

[9] KurachiS, HitomiY, FurukawaM, et al.. Role of intron I in expression of the human factor IX gene. J Biol Chem, 1995, 270(10): 5276-5281

[10] ChangJ, JinJ, LollarP, et al.. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem, 1998, 273(20): 12089-12094

[11] OhmoriT, MimuroJ, TakanoK, et al.. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J, 2006, 20(9): 1522-1524

[12] NathwaniAC, TuddenhamEG, RangarajanS, et al.. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011, 365(25): 2357-2365

[13] GeorgeLA, SullivanSK, GiermaszA, et al.. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med, 2017, 377(23): 2215-2227

[14] MiesbachW, MeijerK, CoppensM, et al.. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood, 2018, 131(9): 1022-1031

[15] RangarajanS, WalshL, LesterW, et al.. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med, 2017, 377(26): 2519-2530

[16] ChowdaryP, ShapiroS, MakrisM, et al.. Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. N Engl J Med, 2022, 387(3): 237-247

[17] XueF, LiH, WuX, et al.. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol, 2022, 9(7): e504-e513

[18] First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC). 2022.

[19] JasinM, HaberJE. The democratization of gene editing: Insights from site-specific cleavage and double-strand break repair. DNA Repair (Amst), 2016, 44: 6-16

[20] LiH, HaurigotV, DoyonY, et al.. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature, 2011, 475(7355): 217-221

[21] MiyaokaY, BermanJR, CooperSB, et al.. Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing. Sci Rep, 2016, 6: 23549

[22] ChuVT, WeberT, WefersB, et al.. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol, 2015, 33(5): 543-548

[23] LiuC, ZhangL, LiuH, et al.. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release, 2017, 266: 17-26

[24] RanFA, CongL, YanWX, et al.. In vivo genome editing using Staphylococcus aureus Cas9. Nature, 2015, 520(7546): 186-191

[25] OhmoriT, NagaoY, MizukamiH, et al.. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep, 2017, 7(1): 4159

[26] WangL, YangY, BretonCA, et al.. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. Blood, 2019, 133(26): 2745-2752

[27] ChenH, ShiM, GilamA, et al.. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep, 2019, 9(1): 16838

[28] LuoS, LiZ, DaiX, et al.. CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A. Front Cell Dev Biol, 2021, 9: 672564

[29] ChenJ, AnB, YuB, et al.. CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs. Haematologica, 2021, 106(3): 829-837

[30] HanJP, KimM, ChoiBS, et al.. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci Adv, 2022, 8(3): eabj6901

[31] StephensCJ, LauronEJ, KashentsevaE, et al.. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. J Control Release, 2019, 298: 128-141

[32] ShiQ, CarmanCV, ChenY, et al.. Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Adv, 2020, 4(10): 2272-2285

[33] ChenY, SchroederJA, GaoC, et al.. In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. J Cell Physiol, 2021, 236(1): 354-365

[34] GuanY, MaY, LiQ, et al.. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med, 2016, 8(5): 477-488

[35] Louis JeuneV, JoergensenJA, HajjarRJ, et al.. Preexisting anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods, 2013, 24(2): 59-67

[36] LiuQ, HuangW, ZhangH, et al.. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther, 2014, 21(8): 732-738

[37] DuanD, SharmaP, YangJ, et al.. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol, 1998, 72(11): 8568-8577

[38] GriegerJC, SamulskiRJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol, 2012, 507: 229-254

[39] CecchiniS, NegreteA, KotinRM. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther, 2008, 15(11): 823-830

[40] HanHA, PangJKS, SohBS. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med (Berl), 2020, 98(5): 615-632

[41] HurstS, WarrenC, PasiKJ. Gene Therapy in Hemophilia: An Assessment of Hematologist’s Knowledge Gaps and Attitudes. Blood, 2018, 132(Supplement 1): 3485